Biomarkers /
CEP85L
Back to Biomarkers List
Associated Diseases
Overview
CEP85L is altered in 0.05% of all cancers with lung adenocarcinoma, dedifferentiated liposarcoma, breast invasive ductal carcinoma, colon adenocarcinoma, and anaplastic ganglioglioma having the greatest prevalence of alterations [3].
The most common alterations in CEP85L are CEP85L-ROS1 Fusion (0.04%) and CEP85L-PDGFRB Fusion (0.03%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.